Women should not take GLP-1s or other weight loss medications while pregnant, breastfeeding, or trying to conceive
The network evidence diagram is shown in Figure 3
The aim should be to gather enough data to make informed decisions , not to create a second job
Obesity is defined by a BMI greater than or equal to 25 kg/m, while overweight is defined as a BMI ranging from 23.00 to 24.99 kg/m
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Birth control pills rely on consistent absorption timing for effectiveness
